Facility rendering of new Orca Bio site in Sacramento, CA

Or­ca Bio looks to in­crease its cell ther­a­py man­u­fac­tur­ing ca­pac­i­ty with a new fa­cil­i­ty in Sacra­men­to

While Or­ca Bio has net­ted some ma­jor mile­stones, such as a $192 mil­lion Se­ries D and a re­gen­er­a­tive med­i­cine ad­vanced ther­a­py (RMAT) des­ig­na­tion from the FDA, the com­pa­ny is look­ing to step up things on the man­u­fac­tur­ing side of the busi­ness.

Or­ca Bio will ex­pand its man­u­fac­tur­ing ca­pa­bil­i­ties by con­struct­ing a new 100,000-square-foot com­mer­cial fa­cil­i­ty in Sacra­men­to, CA.

In an in­ter­view with End­points News, Or­ca Bio COO Jeroen Bekaert said the biotech is now evolv­ing in­to a late-stage cell ther­a­py com­pa­ny and is start­ing its Phase III with the Or­ca-T prod­uct, which has in­creased their need for man­u­fac­tur­ing space.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.